Ensaio de fase 1/2 de Evomela para transplante autólogo em mieloma: otimização do esquema e comparação combinada com MEL200
HematologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Blood advances
- Publicado em
- 1 ago 2026
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Phase 1/2 trial of Evomela for autologous transplant in myeloma: schedule optimization and matched comparison with MEL200
Qaiser Bashir, Peter F Thall, Jitesh D Kawedia, Xun Xu, Cristina G Knape, Ruby Delgado, Yago Nieto, Neeraj Saini, Yosra M Aljawai, Samer A Srour et al.
Descritores MeSH
- Melphalan
- Hematopoietic Stem Cell Transplantation
- Multiple Myeloma
- Humans
- Male
- Middle Aged
- Transplantation, Autologous
- Adult
- Transplantation Conditioning
- Aged
Veja também
Estudos relacionados
- Efficacy and safety profile of busulfan plus low-dose melphalan (BUMEL) versus high-dose melphalan (MEL200) as a conditioning regimen for autologous hematopoietic stem cell transplantation (auto-HSCT) in multiple myeloma patients: a systematic review and meta-analysis
- Modest survival benefits of autologous stem cell transplantation in multiple myeloma with renal impairment: a critical appraisal of the pre-antibody era
- High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial
- Role of Autologous Transplant in Newly Diagnosed Multiple Myeloma Patients Treated with Novel Triplets: A Systematic Review and Meta-Analysis
- International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma
- EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma